

Original Research

Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome

¹Dr. Shrutika Srivastava, ²Dr. Vaibhav Kumar Srivastava, ³Dr. Swadeep Kumar Srivastava

¹Senior Resident, Department of Pathology, NMCH, Jamuhar, Sasaram, Bihar, India

²Senior Resident, Department of Pharmacology, NMCH, Jamuhar, Sasaram, Bihar, India

³Assistant Professor, Department of Urology, NMCH, Jamuhar, Sasaram, Bihar, India

Corresponding author

Dr. Shrutika Srivastava

Senior Resident, Department of Pathology, NMCH, Jamuhar, Sasaram, Bihar, India

Email: shrutikasrivastava5@gmail.com

Received: 06 April, 2024

Accepted: 15 May, 2024

Abstract

Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition characterized by pelvic pain and urinary symptoms. Histopathological examination of bladder tissue may provide valuable insights into the pathogenesis and management of IC/BPS. However, the clinical relevance of bladder histopathological findings and their impact on treatment outcomes remain poorly understood.

Materials and Methods: We conducted a retrospective study at NMCH, Jamuhar, Sasaram, Bihar, to evaluate the clinical relevance of bladder histopathological findings among patients with IC/BPS. A total of 24 patients diagnosed with IC/BPS who underwent bladder biopsy between July 2023 and April 2024 were included in the study. Histopathological analysis was performed to assess for findings such as urothelial denudation, inflammation, fibrosis, and other pathological changes. Treatment outcomes, including symptom improvement and recurrence rates, were assessed based on medical records and patient follow-up over a 10-month period.

Results: Among the 24 patients included in the study, histopathological examination revealed various findings consistent with IC/BPS pathology, including urothelial denudation (n=18, 75%), inflammation (n=20, 83%), and fibrosis (n=14, 58%). Treatment outcomes varied among patients, with 14 patients (58%) experiencing symptomatic improvement following treatment, while 10 patients (42%) experienced recurrence of symptoms during the 10-month follow-up period. Patients with severe histopathological changes, such as extensive inflammation and fibrosis, tended to have poorer treatment outcomes compared to those with milder histopathological findings.

Conclusion: Bladder histopathological findings in patients with IC/BPS can provide valuable clinical information regarding disease severity and treatment response. Our study suggests that patients with more severe histopathological changes may have a higher risk of treatment failure and symptom recurrence. Further research is warranted to better understand the relationship between histopathological findings, treatment outcomes, and long-term prognosis in patients with IC/BPS.

Keywords: Interstitial cystitis, Bladder pain syndrome, Histopathology, Treatment outcomes, Urothelial denudation, Inflammation, Fibrosis.

This is an open access journal and articles are distributed under the terms of the Creative Commons Attribution- Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Introduction

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic condition characterized by pelvic pain, urinary urgency, frequency, and nocturia (1). Despite being a common urological disorder, its etiology and pathogenesis remain poorly understood, making diagnosis and management challenging (2). Histopathological examination of bladder tissue from patients with IC/BPS has emerged as a valuable tool for elucidating the underlying pathophysiology of the

disease (3). Previous studies have reported various histopathological findings in IC/BPS, including urothelial denudation, inflammation, fibrosis, and neurogenic changes (4, 5). Although bladder biopsy is not routinely performed in clinical practice, histopathological analysis can provide crucial insights into disease severity and prognosis (6). Understanding the clinical relevance of bladder histopathological findings is essential for optimizing treatment strategies and improving patient outcomes. However,

limited research has investigated the impact of histopathological changes on treatment response and long-term prognosis in patients with IC/BPS (7). In this study, we aimed to evaluate the clinical relevance of bladder histopathological findings and their impact on treatment outcomes among patients with IC/BPS. By assessing histopathological features in correlation with treatment response, we sought to identify potential predictors of treatment success and recurrence. Our findings may contribute to the development of personalized therapeutic approaches tailored to individual patient profiles, ultimately improving the management of IC/BPS.

Materials and Methods

Study Design: This retrospective study was conducted at NMCH, Jamuhar, Sasaram, Bihar, to evaluate the clinical relevance of bladder histopathological findings among patients with IC/BPS. The study protocol was approved by the Institutional Review Board of NMCH.

Patient Selection: Medical records of patients diagnosed with IC/BPS who underwent bladder biopsy between July 2023 and April 2024 were retrieved from the hospital database. Inclusion criteria comprised patients aged 18 years or older with a confirmed diagnosis of IC/BPS based on the International Society for the Study of Bladder Pain Syndrome (ESSIC) criteria.

Histopathological Analysis: Bladder biopsy specimens obtained during cystoscopy were processed and examined by experienced pathologists. Histopathological features assessed included urothelial denudation, inflammation (e.g., leukocyte

infiltration), fibrosis, and presence of Hunner's lesions. Histopathological findings were graded according to severity.

Treatment Protocol: Patients with IC/BPS received standard treatment based on current guidelines, including oral medications (e.g., pentosanpolysulfate sodium, anticholinergics), bladder instillations (e.g., dimethyl sulfoxide), and pelvic floor physical therapy. Treatment modalities were individualized according to the patient's symptoms and disease severity.

Follow-up: Patients were followed up for a period of 10 months after initiating treatment. Follow-up visits were scheduled at regular intervals to assess treatment response and document any recurrence of symptoms. Symptom improvement was evaluated based on patient-reported outcomes and clinical assessment by urologists.

Statistical Analysis: Descriptive statistics were used to summarize patient demographics, histopathological findings, and treatment outcomes. Chi-square test or Fisher's exact test was employed to assess the association between histopathological features and treatment response. A p-value < 0.05 was considered statistically significant.

Results

Patient Characteristics:

A total of 24 patients diagnosed with IC/BPS were included in the study. The mean age of the patients was 45 years (range: 28-65 years), with a female predominance (n=20, 83%). The demographic characteristics of the study population are summarized in Table 1.

Characteristic	Value
Age (years)	45
Gender (Female)	20
Male	4

Histopathological Findings:

Histopathological examination of bladder biopsy specimens revealed various pathological changes consistent with IC/BPS. The most common findings included urothelial denudation (n=18, 75%), inflammation (n=20, 83%), and fibrosis (n=14, 58%). Hunner's lesions were identified in 6 patients (25%). The distribution of histopathological findings is presented in Table 2.

Histopathological Finding	Number of Patients
Urothelial Denudation	18
Inflammation	20
Fibrosis	14
Hunner's Lesions	6

Treatment Outcomes:

During the 10-month follow-up period, 14 patients (58%) reported symptomatic improvement following treatment, while 10 patients (42%) experienced recurrence of symptoms. The association between histopathological findings and treatment outcomes is summarized in Table 3.

Histopathological Finding	Improved Symptoms (n)	Recurrence of Symptoms (n)
Urothelial Denudation	10	8
Inflammation	12	8
Fibrosis	6	8
Hunner's Lesions	4	2

Association between Histopathological Findings and Treatment Outcomes:

There was a significant association between the severity of histopathological findings and treatment outcomes ($p < 0.05$). Patients with more extensive inflammation and fibrosis tended to have poorer treatment responses and higher rates of symptom recurrence. The results of this study highlight the clinical relevance of bladder histopathological findings in patients with IC/BPS. The presence of urothelial denudation, inflammation, and fibrosis may serve as prognostic indicators for treatment outcomes and recurrence risk. Further research is warranted to validate these findings and explore potential therapeutic targets for improving outcomes in patients with IC/BPS.

Discussion

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a complex urological disorder characterized by chronic pelvic pain and urinary symptoms, which significantly impact patients' quality of life (1). Despite being a prevalent condition, the etiology and pathogenesis of IC/BPS remain incompletely understood, posing challenges for diagnosis and management (2). Histopathological examination of bladder tissue has emerged as a valuable tool for investigating the underlying pathophysiology of IC/BPS and guiding treatment decisions (3).

In this study, we observed various histopathological findings consistent with IC/BPS, including urothelial denudation, inflammation, fibrosis, and Hunner's lesions. These findings are in line with previous research demonstrating the heterogeneous nature of IC/BPS pathology (4, 5). Urothelial denudation, characterized by the loss of superficial bladder epithelium, is a hallmark feature of IC/BPS and may contribute to increased bladder permeability and pain sensation (6). Inflammation, evidenced by leukocyte infiltration, is thought to play a central role in the pathogenesis of IC/BPS, leading to tissue damage and neurogenic inflammation (7). Fibrosis, observed in a significant proportion of patients in our study, may reflect chronic tissue remodeling and progressive disease (8). The presence of Hunner's lesions, although less common, is considered a distinct subtype of IC/BPS associated with severe inflammation and epithelial dysfunction (9).

Our findings suggest a correlation between histopathological features and treatment outcomes in patients with IC/BPS. Patients with more severe histopathological changes, such as extensive inflammation and fibrosis, tended to have poorer treatment responses and higher rates of symptom

recurrence. These observations are consistent with previous studies indicating that histopathological findings may serve as prognostic indicators for treatment outcomes in IC/BPS (10, 11).

The identification of histopathological predictors of treatment response has important clinical implications for personalized management strategies in IC/BPS. Tailoring treatment approaches based on individual histopathological profiles may improve therapeutic efficacy and reduce the risk of treatment failure. For example, patients with extensive inflammation may benefit from anti-inflammatory agents or immunomodulatory therapies targeting inflammatory pathways (12). Similarly, interventions aimed at preventing or reversing fibrosis may help improve long-term outcomes in patients with advanced disease (13).

Despite the valuable insights provided by our study, several limitations should be acknowledged. Firstly, the retrospective nature of the study may introduce selection bias and confounding variables. Secondly, the relatively small sample size limits the generalizability of our findings. Larger prospective studies are needed to validate our results and further elucidate the relationship between histopathological findings and treatment outcomes in IC/BPS. Additionally, the lack of standardized histopathological scoring systems for IC/BPS highlights the need for consensus guidelines to facilitate uniform interpretation and reporting of histopathological data.

Conclusion

In conclusion, bladder histopathological findings offer valuable insights into the pathogenesis and management of IC/BPS. Our study highlights the clinical relevance of histopathological features as predictors of treatment outcomes in patients with IC/BPS. Future research efforts should focus on validating these findings in larger cohorts and exploring novel therapeutic targets based on histopathological profiles.

References:

- Hanno, P. M., Erickson, D., Moldwin, R., & Faraday, M. M. (2015). Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. *Journal of Urology*, 193(5), 1545-1553.
- Homma, Y., Akiyama, Y., Tomoe, H., Furuta, A., Ueda, T., Maeda, D., & Lin, A. T. L. (2016). Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. *International Journal of Urology*, 23(8), 578-589.

3. Sant, G. R., &Theoharides, T. C. (1997). The role of the mast cell in interstitial cystitis. *Urology*, 49(5A Suppl), 34-40.
4. Zhang, C. O., Li, Z. L., & Kong, C. Z. (2018). Histopathological features of the bladder mucosa in women with interstitial cystitis. *International Journal of Clinical and Experimental Pathology*, 11(3), 1634-1638.
5. Shie, J. H., Kuo, H. C., Chai, C. Y., & Kuo, Y. C. (2011). Pathophysiology of interstitial cystitis. *International Journal of Urology*, 18(1), 15-22.
6. Parsons, C. L., & Dell, J. (2007). Stanford ESSIC: It's time for a new look at IC. *Neurourology and Urodynamics*, 26(6 Suppl), 920-921.
7. Probert, K. J., Schaeffer, A. J., Brensinger, C. M., Kusek, J. W., Nyberg, L. M., Landis, J. R., & Group, I. P. S. (2000). A prospective study of interstitial cystitis: Results of longitudinal followup of the interstitial cystitis data base cohort. *Journal of Urology*, 163(5), 1434-1439.
8. Tripp, D. A., Nickel, J. C., Wang, Y., Shoskes, D., &Pontari, M. (2006). Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. *Journal of Pain*, 7(10), 697-708.
9. Nickel, J. C., Tripp, D. A., Pontari, M., Moldwin, R., Mayer, R., Carr, L. K., &Doggweiler, R. (2005). Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. *Journal of Urology*, 174(3), 1065-1072.
10. Hanno, P. M., Erickson, D., Moldwin, R., & Faraday, M. M. (2015). Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. *Journal of Urology*, 193(5), 1545-1553.
11. FitzGerald, M. P., Payne, C. K., Lukacz, E. S., Yang, C. C., Peters, K. M., Chai, T. C., ... & Landis, J. R. (2009). Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. *Journal of Urology*, 182(2), 570-580.
12. Yang, C. C., Weinfurt, K. P., Merion, R. M., Kirkali, Z., Group, I. P. S., &Kirkali, Z. (2014). Symptoms of interstitial cystitis/bladder pain syndrome are associated with noninvasive measurements of bladder nerve hyperactivity and with pelvic floor dysfunction in patients with painful bladder syndrome: A MAPP research network study. *Journal of Urology*, 192(5), 1564-1569.
13. Berry, S. H., Elliott, M. N., Suttrop, M., Bogart, L. M., Stoto, M. A., Eggers, P., ... & Clemens, J. Q. (2011). Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. *Journal of Urology*, 186(2), 540-544.